Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis

[PR Newswire] – INDIANAPOLIS, Jan. 19, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that Lilly has submitted a new drug application (NDA) to the U.S. Food … Read more on this. Eli Lilly and Company (LLY) , valued at $88.75B, began trading this morning at $82.31. Today, shares have traded between $82.09 and $84.80 per share and has traded between $68.31 and $92.85 over the past year. Priced at 23.69x this year’s forecasted earnings, LLY shares are relatively expensive compared to the industry’s -2.14x forward p/e ratio. And for passive income investors, the company pays shareholders $2.04 per share annually in dividends, yielding 2.47%. According to a consensus of 19 analysts, the earnings estimate of $0.78 per share would be $0.03 better than the year-ago quarter and a $0.01 sequential increase. The full-year EPS estimate is $3.43, which would be a $0.65 better than last year. The quarterly earnings estimate is predicated on a consensus revenue forecast of $5.31 Billion. If reported, that would be a 3.71% increase over the year-ago quarter. More recently, BMO Capital Markets upgraded LLY from Market Perform to Outperform (Nov 13, 2015). Previously, Credit Suisse upgraded LLY from Neutral to Outperform. When considering if the stock is under or overvalued, the average price target is $99.25, which is 20.58% above where the stock opened this morning. See more in (NYSE:LLY) Similar Articles: Company Update (NYSE:LLY): Yabao Pharmaceuticals Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment Market Update: Eli Lilly & Company (NYSE:LLY) – EXCLUSIVE-US insurers hold back Lilly’s death-defying diabetes drug Market Update (NYSE:LLY): Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis